Genmab — November 2018
-
Fantastisk måned vi har haft - først kyler hysteriske investorer os i helvedesdybet pga. nogle (indtil andet vides) engangsrabatter og små bitte forsinkelser ift. oprindeligt udmeldte MAIA-data datoer.. så kører vi op igen da forventeligt fine MAIA-data og forventeligt gode ASH-data kommer. Hvem der havde haft en ekstra formue at indkøbe for i 800.......
! -
Genmab har igennem innovation fået frembragt nogle unikke duobodies/haxabodies/duohexabodies der er yderst potente. Nu skal de gennem nåleøjet i kliniske forsøg for muligvis blive til cash cows. Det bliver interessant at følge. Dara sc er home run og bjerget er daras (citat fra FS).
-
do we know that SC eliminates the initial administration issues?
-
or is that something we still need to see from the studies?
-
not a complete answer JV, but close, maybe we hear more in the actual presentation https://ash.confex.com/ash/2018/webprogram/Paper113590.html
-
It looks like there still is a bit of IRRs in the first dose, but much les than IV: The incidence (16%) and severity of IRRs (mostly grade 1-2) with DARA SC was low, the majority of which occurred on Cycle 1 Day 1, and no discontinuations due to IRRs were observed.
-
from what i recall - SC is being tested "stand-alone". The first dose is also SC. But I'm guessing an SC dose as an out patient is much easier/faster than the two-day IV first dose
-
Bulder - do you know if SC first dose is administered at home or under supervision?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind